Skip to main content
. 2025 Sep 3;14(4):e00334. doi: 10.1097/XCE.0000000000000334

Table 3.

Reasons for combining dapagliflozin and sitagliptin

Reason Number of patients (%)
Uncontrolled glycemia 151 (89.9)
Weight gain 56 (33.3)
Hypoglycemia due to other GLP-1 analog/insulin/other OADs 40 (23.8)
Glycemic variability 127 (75.6)
Hospitalization because of cardiovascular disease 83 (49.4)

GLP-1, glucagon-like peptide 1; OAD, oral antidiabetic drug.